| Literature DB >> 35067678 |
Daniel Moualed1,2, Jonathan Wong3,4, Owen Thomas5, Calvin Heal6, Rukhtam Saqib5, Cameron Choi5, Simon Lloyd1,7, Scott Rutherford8, Emma Stapleton1, Charlotte Hammerbeck-Ward8, Omar Pathmanaban7,8, Roger Laitt5, Miriam Smith9, Andrew Wallace9, Mark Kellett10, Gareth Evans9, Andrew King3,8, Simon Freeman11.
Abstract
This study explores the natural history of vestibular, trigeminal and lower cranial nerve schwannomas (VS, TS, LCNS) in patients with Neurofibromatosis type 2 (NF2), to understand how pathogenic variants (PVs) of the NF2 gene affect tumour burden and growth rate, via a retrospective analysis of a UK NF2 centre database and imaging. VS, TS and LCNS location and size were measured in accordance with a standardised protocol. PVs were categorised in accordance with the UK NF2 Genetic Severity Score (GSS). 153 patients (age 5-82) had 458 schwannomas, of which 362 were previously untreated comprising: 204 VS, 93 TS, and 65 LCNS (IX, X, XI). 322 schwannomas had sequential imaging allowing growth rate analysis with a mean follow-up of 45 months. VS were universally present, and bilateral in 146/153 cases. 65% of tumours grew >2 mm during the study period at mean rate 2.0 mm/year. Significant association was found between increasing GSS and growth rate. TS occurred in 66/153 patients (bilateral in 27/153); 31% of tumours showed growth (mean 1.8 mm/yr). Significant increase in tumour prevalence was noted with increasing GSS. LCNS were found in 47/153 patients (bilateral in 19/153); 27% of tumours showed growth (mean 1.9 mm/yr). The trend for increased prevalence with increasing GSS did not reach significance. VS growth rate was significantly influenced by GSS and they were much more likely to grow than TS and LCNS. TS prevalence also correlated with increasing GSS.Entities:
Mesh:
Year: 2022 PMID: 35067678 PMCID: PMC8991183 DOI: 10.1038/s41431-021-01029-y
Source DB: PubMed Journal: Eur J Hum Genet ISSN: 1018-4813 Impact factor: 4.246